Ascendis pharma Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Ascendis pharma Contact Number

Contact Us Ascendis Pharma US

7 hours ago Ascendispharma.us Show details

49 6221 99

Im Neuenheimer Feld 584 D-69120 Heidelberg Germany Tel: +49 6221 99 89 00 Geschäftsführerin: Lotte Sønderbjerg Amtsgericht Mannheim: HRB 337385 USt-IdNr. DE813586261

Category: Contact SupportShow more

Ascendis Contact us

8 hours ago Ascendishealth.com Show details

012 346 2095

Animal Health: Soné Briers [email protected]; 012 346 2095; Consumer Brands: Odille Bielderman [email protected] 011 036 9519 Charlene Du Toit [email protected]; 011 036 9432; Pharma: Karen Scholtz [email protected]; 011 036 9570; Medical: Chris Swanepoel …

Category: Contact SupportShow more

Ascendis Pharma Endocrinology Division A/S Company …

6 hours ago Dnb.com Show details

Phone. +45-21377063. Company Description. Ascendis Pharma Endocrinology Division A/S is located in Hellerup, Hovedstaden, Denmark and is part of the Pharmaceutical Manufacturing Industry. Ascendis Pharma Endocrinology Division A/S has 16 total employees across all of its locations and generates $424,640 in sales (USD).

Employees: 16
Phone: 21377063
Location: Tuborg Boulevard 12C/O Ascendis Pharma A/S, Hellerup, 2900

Category: Contact NumberShow more

ASCENDIS PHARMA (PTY) LTD Company Profile …

9 hours ago Dnb.com Show details

ASCENDIS PHARMA (PTY) LTD is located in GAUTENG, Gauteng, South Africa and is part of the Professional and Commercial Equipment and Supplies Merchant Wholesalers Industry. ASCENDIS PHARMA (PTY) LTD has 203 total employees across all of its locations and generates $14.92 million in sales (USD). (Sales figure is modelled).

Employees: 203
Phone: 075-8800
Location: 31 GEORGIAN CRES EASTBRYANSTON, GAUTENG, 2191, GP

Category: Contact NumberShow more

Ascendis Pharma Crunchbase Company Profile & Funding

5 hours ago Crunchbase.com Show details

650 352 8389

Contact Email [email protected]ascendispharma.com Phone Number 650 352 8389 Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms.

Founded: 2006
Founder: Jan Moller Mikkelsen

Category: Contact NumberShow more

Ascendis Pharma: We’ve got making a difference for

7 hours ago Ascendispharma.com Show details

Ascendis Pharma takes no responsibility for the content of such external website CONFIRM DENY You are about to access www.ascendispharma.us, which includes information intended for …

Category: Contact NumberShow more

Ascendis Pharma, Ophthalmology Division A/S Company

6 hours ago Dnb.com Show details

Ascendis Pharma, Ophthalmology Division A/S is located in Hellerup, Hovedstaden, Denmark and is part of the Pharmaceutical Manufacturing Industry. Ascendis Pharma, Ophthalmology Division A/S has 16 total employees across all of its locations and generates $424,640 in sales (USD). (Employees and Sales figures are modelled).

Category: Contact NumberShow more

Ascendis Crunchbase Company Profile & Funding

8 hours ago Crunchbase.com Show details

27 21 701

Contact Email [email protected]ascendis.co.za Phone Number 27 21 701 2232 Ascendis’ African footprint is a key growth objective and its plant & animal health division opens new distribution channels for the group into 20 African countries.

Category: Contact NumberShow more

Ascendis Pharma A/S Email Format ascendispharma.com …

2 hours ago Rocketreach.co Show details

Ascendis Pharma A/S Email Format. Ascendis Pharma A/S uses 6 email formats, with first_initial last (ex. [email protected]) being used 40.8% of the time. Get Verified Emails for Ascendis Pharma A/S Employees. Ascendis Pharma A/S's Email Format. Percentage.

Category: Contact NumberShow more

CoManager Ascendis Pharma Kempen

2 hours ago Kempen.com Show details

The transaction was executed on the back of strong momentum as Ascendis Pharma achieved a number of major clinical and regulatory milestones over the past several months. The capital raise was upsized from its originally envisaged amount of USD 500 million due to strong demand and was priced tightly at a discount of 3.8% to the last ADS closing

Category: Contact NumberShow more

Contact Us Ascendia Pharmaceuticals

5 hours ago Ascendiapharma.com Show details

732-640-0058

Contact T: 732-640-0058 ext. 601 (operator) T: 732-638-4028 (technical or business collaboration) F: 732-658-4267

Category: Contact SupportShow more

IR Contact Ascendis Pharma

7 hours ago Investors.ascendispharma.com Show details

Primary IR Contact. Scott T. Smith. Chief Financial Officer. Ascendis Pharma. E-mail: [email protected]ascendispharma.com. To request information, please fill out and submit the form below: Personal Information. Required fields denoted by an asterisk (*). First Name.

Category: Contact SupportShow more

Ascendis

7 hours ago Ascendishealth.com Show details

COVID-19 Corona Virus South African Resource Portal - sacoronavirus.co.za Home; About us. Our people. Executive Management; Senior Leadership EU & RSA; Governance

Category: Contact NumberShow more

EX99.1

4 hours ago Sec.gov Show details

(650) 374-6343

SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. Number of shares used for calculation (basic and diluted) 53,848,166 : 48,207,661 Media contact: Tim Lee : Melinda Baker: Ascendis Pharma : Ascendis Pharma (650) 374-6343 (650) 709-8875: tle

Category: Contact NumberShow more

Ascendis Pharma: We’ve got making a difference for

6 hours ago Ascendispharma.us Show details

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting September 29, 2021 September 22, 2021

Category: Contact NumberShow more

Ascendis The Compounding Pharmacy

9 hours ago Ascendishealth.com Show details

Compounding combines an ageless art with the latest medical knowledge and state-of-the-art technology, allowing specially trained professionals to prepare customized medications to meet each patient’s specific needs. Compounding is fundamental to the profession of pharmacy and was a standard means of providing prescription medications before

Category: Contact NumberShow more

Leadership Ascendis Pharma

7 hours ago Ascendispharma.com Show details

President and CEO. Expand. Jan Møller Mikkelsen founded Ascendis Pharma and has served as President and Chief Executive Officer as well as Board member since December 2007. From 2002 to 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S, now traded under the name Veloxis Pharmaceuticals A/S.

Category: Contact NumberShow more

Oncology Ascendis Pharma US

4 hours ago Ascendispharma.us Show details

Developing therapies that facilitate the immunity cycle. Designed to activate antigen-presenting cells and enhance antigen presentation and, thereby, promote activation of cytotoxic immune cells (steps 2 and 6). Designed to aid T-cell and NK-cell expansion, priming and activation, as well as infiltration of immune cells in tumors. (steps 3 and 5).

Category: Contact NumberShow more

Privacy Policy Ascendis Pharma

2 hours ago Ascendispharma.com Show details

Ascendis Pharma will only process your personal information in a pseudonymous form. This means that a unique trial identification number will be assigned to you by the study doctor and all personal information shared with Ascendis Pharma will only be linked to this unique trial identification number. Ascendis Pharma will not know your name.

Category: Contact NumberShow more

Did Hedge Funds Make The Right Call On Ascendis Pharma A/S

5 hours ago Finance.yahoo.com Show details

Of the funds tracked by Insider Monkey, Peter Kolchinsky's RA Capital Management has the number one position in Ascendis Pharma A/S (NASDAQ:ASND), worth close to $553.5 million, corresponding to

Category: Contact NumberShow more

Ascendis Pharma announces formation of VISEN Pharmaceuticals

1 hours ago Biospectrumasia.com Show details

Ascendis Pharma, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, has announced the formation of VISEN Pharmaceuticals (Visen), a joint venture with an investor syndicate led by Vivo Capital, to develop, manufacture and commercialize the company’s endocrinology rare disease therapies in Greater China, which includes

Category: Contact NumberShow more

Ascendis Pharma A/S Announces U.S. Commercial Launch of

9 hours ago Apnews.com Show details

(650) 374-6343

Media Contact: Tim Lee Melinda Baker: Ascendis Pharma Ascendis Pharma (650) 374-6343 (650) 709-8875: [email protected] [email protected] Patti Bank Westwicke Partners (415) 513-1284 [email protected] [email protected]

Category: Contact NumberShow more

Ascendis Pharma A/S (ASND) Company Profile & Facts Yahoo

4 hours ago Finance.yahoo.com Show details

See the company profile for Ascendis Pharma A/S (ASND) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and

Category: Contact NumberShow more

About Us

Just Now Ascendisdirect.com Show details

About Us. Ascendis Health Direct is a leading network marketing company specialising in the health industry. As a company we are committed to making a difference in the daily lives of many families in Africa and are passionate about building wealth for people through wellness. Ascendis Health Direct offers people from all backgrounds, the

Category: Contact NumberShow more

INFORMATION MANUAL IN TERMS OF SECTION 51 OF …

4 hours ago Ascendishealth.com Show details

PAIA MANUAL Page 3 of 29 1. DEFINITIONS 1.1 The Act means the Promotion of Access to Information Act, 2000 (Act No. 2 of 2000); 1.2 Company means Ascendis Health Ltd, a public company duly registered in terms of the Companies Act, 2008 of South Africa under the registration number 2008/005856/06 and having its registered address at 22 Sloane Street, Bryanston, including its …

Category: Contact NumberShow more

Oncology Ascendis Pharma

5 hours ago Ascendispharma.com Show details

Developing therapies that facilitate the immunity cycle. Designed to activate antigen-presenting cells and enhance antigen presentation and, thereby, promote activation of cytotoxic immune cells (steps 2 and 6). Designed to aid T-cell and NK-cell expansion, priming and activation, as well as infiltration of immune cells in tumors. (steps 3 and 5).

Category: Contact NumberShow more

Ascendis Pharma A/S 29918791 Hellerup Se Regnskaber

Just Now Proff.dk Show details

Proff.dk giver dig firmainformation om Ascendis Pharma A/S, 29918791. Find vejbeskrivelse, kontaktinfo, regnskabstal, ledelse, bestyrelse og ejere.

Category: Contact NumberShow more

Review

Just Now Accessdata.fda.gov Show details

On August 26, 2020, Ascendis Pharma submitted the proposed proprietary name, *** to BLA 761177 because *** was not accepted by the EMA and Ascendis Pharma wanted to have one global name for their product. However, on September 9, 2020 Ascendis withdrew the request for the proposed proprietary name ***.

Category: Contact NumberShow more

Ascendis Pharma Funding, Financials, Valuation & Investors

4 hours ago Crunchbase.com Show details

Ascendis Pharma has raised a total of $85.7M in funding over 3 rounds. Their latest funding was raised on Jan 1, 2017 from a Post-IPO Equity round. Ascendis Pharma is registered under the ticker NASDAQ:ASND . Their stock opened with $18.00 in its Jan 28, 2015 IPO. Ascendis Pharma is …

Category: Contact NumberShow more

Ascendis Senior Leadership EU & RSA

1 hours ago Ascendishealth.com Show details

Dr Michael Neoptolemou is a seasoned academic and a PhD graduate whose illustrious career spans the public, higher education and corporate sectors. He has been a member of the top management of Remedica since 2014. He joined the board of directors in 2017 and currently serves as its chairman. In July 2019, he was appointed as the company’s

Category: Contact NumberShow more

ASND Ascendis Pharma A/S • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

(650) 709-8875

Media contact: Melinda Baker Ascendis Pharma (650) 709-8875 [email protected]

Category: Contact NumberShow more

Acendis Pharma's TransCon hGH BLA Decision Delayed Pure

6 hours ago Purepharmanews.com Show details

The US FDA notified Ascendis Pharma that information the company submitted in connection with the FDA’s ongoing review of the biologics license application (BLA) for TransCon hGH (lonapegsomatropin) for the treatment of paediatric growth hormone deficiency (GHD) constituted a major amendment to the BLA. Accordingly, the FDA has extended the Prescription Drug User Fee Act …

Category: Contact NumberShow more

Ascendis Pharma A/S Announces Share Repurchase Program

7 hours ago Biospace.com Show details

The maximum number of ADS that can be repurchased on a single trading day may not exceed 10% of the average daily trading volume of Ascendis Pharma A/S ADS, in the prior full four weeks of trading. At least once every seven trading days, Ascendis Pharma A/S will issue an announcement in respect of the transactions made under the repurchase program.

Category: Contact NumberShow more

Annali Maree National Account Manager Ascendis Health

8 hours ago Za.linkedin.com Show details

View Annali Maree’s profile on LinkedIn, the world’s largest professional community. Annali has 2 jobs listed on their profile. See the complete profile on LinkedIn and discover Annali’s connections and jobs at similar companies.

Title: National Account Manager at …
Location: Johannesburg
Connections: 194

Category: Contact NumberShow more

Here's Why Ascendis Pharma Is Rocketing Higher Today The

7 hours ago Fool.com Show details

Shares of Ascendis Pharma ( NASDAQ:ASND) , a biopharmaceutical company committed to extended-release technology, are soaring after the company released pivotal trial results for its lead candidate

Category: Contact NumberShow more

Ascendis Pharma A/S Reports Second Quarter 2021 Financial

4 hours ago Finance.yahoo.com Show details

Number of shares used for calculation (basic and diluted) 53,848,166. 48,207,661. Media contact: Melinda Baker Ascendis Pharma (650) …

Category: Contact NumberShow more

US clears Ascendis' onceweekly paediatric growth hormone

5 hours ago Pharmasources.com Show details

Cuts number of injections days by 86%. The FDA approval, which boosted Ascendis shares about 27% after-hours, also includes the new Skytrofa auto-injector and cartridges that allow the medicine to be stored at room temperature for up to six months.

Category: Contact NumberShow more

Ascendis Pharma A/S Reports First Quarter 2021 Financial

2 hours ago Investors.ascendispharma.com Show details

Ended the first quarter of 2021 with cash, cash equivalents and marketable securities totaling €771.1 million. For the first quarter, Ascendis Pharma reported a net loss of €62.8 million, or €1.17 per share (basic and diluted) compared to a net loss of €63.3 million, or €1.32 per share (basic and diluted) for the same period in 2020.

Category: Contact NumberShow more

THE HOUSE OF BUSBY M2004028454 South Africa

5 hours ago B2bhint.com Show details

Was founded on October 4, 2004 with identification number M2004028454 based on 35 FRICKER ROAD, ILLOVO, ILLOVO, GAUTENG, 2196. Home Archive About Contact. ASCENDIS MEDICAL BESSIE RETAIL TRADING PHARMACHEM PHARMACEUTICALS ASCENDIS PHARMA ELIXR BRANDS ASCENDIS HEALTH SURGICAL INNOVATIONS ASCENDIS SKIN AND BODY …

Category: Contact NumberShow more

Ascendis preps global TransCon expansion

4 hours ago Outsourcing-pharma.com Show details

Ascendis has previously said there are “only a limited number of companies on a worldwide basis ” with the sort of capacity it needs to manufacture TransCon hGH. The building up of the secondary supplier and the launch preparations, which Mikkelsen said entail “manufacturing on the highest speed every day ,” are evident in Ascendis’ financial results.

Category: Contact NumberShow more

Ascendis Pharma A/S Announces Share Repurchase Program

8 hours ago Finance.yahoo.com Show details

The maximum number of ADS that can be repurchased on a single trading day may not exceed 10% of the average daily trading volume of Ascendis Pharma A/S ADS, in …

Category: Contact NumberShow more

Kochava Media Index Ascendis Health Competitors, Reviews

4 hours ago Media-index.kochava.com Show details

Ascendis Health has more than 10 products sitting in the number one spot in the South African market, and a further 15 dominate the rankings in second position. This market strength is reinforced by our commitment to quality and customer satisfaction, and by the strategic and sustainable vision upheld by our executives, board members and employees.

Category: Contact NumberShow more

Patrick Duffy Cupertino, California, United States

1 hours ago Linkedin.com Show details

Patrick Duffy Student at Loyola Marymount University, College of Business Administration Cupertino, California, United States 65 connections

Title: Student at Loyola Marymount …
Location: Cupertino, California, United States
Connections: 65

Category: Contact NumberShow more

Ascendis Pharma A/S American Depositary Shares (ASND

3 hours ago Nasdaq.com Show details

Ascendis Pharma A/S American Depositary Shares including the number of shares held by those institutions in a firm, along with recent purchases and sales information. Contact Careers

Category: Contact NumberShow more

The Annual General Meeting of Ascendis Pharma A/S will be

3 hours ago Investors.ascendispharma.com Show details

The Annual General Meeting of Ascendis Pharma A/S will be held on May 29, 2018 at 2:00 pm CET at Mazanti-Andersen Korsø Jensen, Amaliegade 10, DK-1256 Copenhagen K, Denmark Name and address: This form must be returned to: Computershare A/S Lottenborgvej 26D DK-2800 Kgs. Lyngby VP-account number:

Category: Contact NumberShow more

Ascendis Pharma (NASDAQ:ASND) Valuation Analysis Macroaxis

Just Now Macroaxis.com Show details

Ascendis Pharma ADR shows a prevailing Real Value of $161.55 per share. The current price of the firm is $162.25. At this time, the firm appears to be fairly valued.Our model approximates the value of Ascendis Pharma ADR from analyzing the firm fundamentals such as return on equity of (78.63) %, and Current Valuation of 7.89 B as well as examining its technical indicators and Probability Of

Category: Contact NumberShow more

Ascendis Pharma A/S (NASDAQ:ASND) Expected to Post

7 hours ago Marketbeat.com Show details

Ascendis Pharma A/S had a negative return on equity of 56.44% and a negative net margin of 9,108.77%. A number of analysts have recently commented on the company. Wedbush restated a "buy" rating and issued a $187.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, August 26th. SVB Leerink upped their target price on

Category: Contact NumberShow more

Ascendis Pharma A/S Announces U.S. Commercial Launch of

8 hours ago Investors.ascendispharma.com Show details

2 days ago · COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes